CA3078900A1 - Oral rifamycin sv compositions - Google Patents

Oral rifamycin sv compositions Download PDF

Info

Publication number
CA3078900A1
CA3078900A1 CA3078900A CA3078900A CA3078900A1 CA 3078900 A1 CA3078900 A1 CA 3078900A1 CA 3078900 A CA3078900 A CA 3078900A CA 3078900 A CA3078900 A CA 3078900A CA 3078900 A1 CA3078900 A1 CA 3078900A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
oral pharmaceutical
rifamycin
composition according
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078900A
Other languages
English (en)
French (fr)
Inventor
Luigi Moro
Luigi Maria Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of CA3078900A1 publication Critical patent/CA3078900A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3078900A 2017-11-10 2018-11-07 Oral rifamycin sv compositions Pending CA3078900A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584226P 2017-11-10 2017-11-10
US62/584,226 2017-11-10
PCT/IB2018/058748 WO2019092614A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Publications (1)

Publication Number Publication Date
CA3078900A1 true CA3078900A1 (en) 2019-05-16

Family

ID=64426987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078900A Pending CA3078900A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Country Status (17)

Country Link
US (3) US11564883B2 (https=)
EP (3) EP4438039A3 (https=)
JP (2) JP2021502382A (https=)
KR (1) KR102747348B1 (https=)
CN (1) CN111328279B (https=)
AR (1) AR114140A1 (https=)
AU (1) AU2018364617B2 (https=)
BR (1) BR112020009171A2 (https=)
CA (1) CA3078900A1 (https=)
DK (1) DK3706724T3 (https=)
ES (1) ES2989706T3 (https=)
FI (1) FI3706724T3 (https=)
IL (1) IL274414B2 (https=)
MX (1) MX2020004706A (https=)
PL (1) PL3706724T3 (https=)
WO (1) WO2019092614A1 (https=)
ZA (1) ZA202002726B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102198A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 内服固形剤
US20220280478A1 (en) * 2021-03-05 2022-09-08 Bausch Health Ireland, Limited Methods of using rifamycin sv for the treatment of sickle cell disease
EP4412588A1 (en) * 2021-10-05 2024-08-14 Cosmo Technologies Ltd An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
KR20080081351A (ko) 2006-01-04 2008-09-09 도꾜 메디칼 앤드 덴탈 유니버시티 간장 질환 치료제 및 간기능 개선제
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8741048B2 (en) 2011-08-30 2014-06-03 Brother Kogyo Kabushiki Kaisha Water-based ink for ink-jet recording and ink cartridge
IN2014DN06662A (https=) 2012-02-13 2015-05-22 Cosmo Technologies Ltd
WO2016003536A1 (en) 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same

Also Published As

Publication number Publication date
AR114140A1 (es) 2020-07-29
PL3706724T3 (pl) 2024-12-16
AU2018364617B2 (en) 2024-11-07
KR20200086285A (ko) 2020-07-16
EP4438039A3 (en) 2024-12-04
JP2021502382A (ja) 2021-01-28
MX2020004706A (es) 2020-09-07
RU2020119035A (ru) 2021-12-10
ES2989706T3 (es) 2024-11-27
WO2019092614A1 (en) 2019-05-16
US12036316B2 (en) 2024-07-16
IL274414B2 (en) 2024-08-01
CN111328279B (zh) 2023-04-14
CN111328279A (zh) 2020-06-23
US11564883B2 (en) 2023-01-31
US20240398699A1 (en) 2024-12-05
DK3706724T3 (da) 2024-10-14
EP4431094A3 (en) 2024-11-20
EP3706724B1 (en) 2024-09-11
IL274414B1 (en) 2024-04-01
JP2023112076A (ja) 2023-08-10
ZA202002726B (en) 2024-09-25
FI3706724T3 (fi) 2024-10-14
AU2018364617A1 (en) 2020-05-07
EP3706724A1 (en) 2020-09-16
IL274414A (en) 2020-06-30
US20200281850A1 (en) 2020-09-10
RU2020119035A3 (https=) 2022-04-20
JP7651620B2 (ja) 2025-03-26
KR102747348B1 (ko) 2024-12-31
BR112020009171A2 (pt) 2020-11-03
EP4431094A2 (en) 2024-09-18
US20230135346A1 (en) 2023-05-04
EP4438039A2 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
US12036316B2 (en) Oral rifamycin SV compositions
JP5968300B2 (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
DuPont Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases
US20180200308A1 (en) Methods of treating colitis
KR20170038810A (ko) 과민성 대장 증후군(ibs)의 재치료 방법
US20130115286A1 (en) Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract
CA2918004C (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN104394691A (zh) 用5-氨基水杨酸治疗过敏性肠道综合症的组合物和方法
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
JP2008535905A (ja) 慢性便秘を治療するためのアカルボース方法と製剤
HK40036103A (en) Oral rifamycin sv compositions
HK40036103B (en) Oral rifamycin sv compositions
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250328

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250328

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250424

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324